186 related articles for article (PubMed ID: 38069037)
21. Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR.
Wassel MMS; Ammar YA; Elhag Ali GAM; Belal A; Mehany ABM; Ragab A
Bioorg Chem; 2021 May; 110():104794. PubMed ID: 33735711
[TBL] [Abstract][Full Text] [Related]
22. Analogue based drug design, synthesis, molecular docking and anticancer evaluation of novel chromene sulfonamide hybrids as aromatase inhibitors and apoptosis enhancers.
Ghorab MM; Alsaid MS; Al-Ansary GH; Abdel-Latif GA; Abou El Ella DA
Eur J Med Chem; 2016 Nov; 124():946-958. PubMed ID: 27770735
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel rigid analogs of 2-naphthol with potent anticancer activity through multi-target topoisomerase I & II and tyrosine kinase receptor EGFR & VEGFR-2 inhibition mechanism.
El-Mawgoud HKA; Fouda AM; El-Nassag MAA; Elhenawy AA; Alshahrani MY; El-Agrody AM
Chem Biol Interact; 2022 Mar; 355():109838. PubMed ID: 35123995
[TBL] [Abstract][Full Text] [Related]
24. Synthesis, Biological Evaluation, and Docking of Dihydropyrazole Sulfonamide Containing 2-hydroxyphenyl Moiety: A Series of Novel MMP-2 Inhibitors.
Wang PF; Qiu HY; Baloch SK; Gong HB; Wang ZC; Zhu HL
Chem Biol Drug Des; 2015 Dec; 86(6):1405-10. PubMed ID: 26061284
[TBL] [Abstract][Full Text] [Related]
25. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
26. Novel Pyrazoloquinolin-2-ones: Design, synthesis, docking studies, and biological evaluation as antiproliferative EGFR-TK inhibitors.
Elbastawesy MAI; Aly AA; Ramadan M; Elshaier YAMM; Youssif BGM; Brown AB; El-Din A Abuo-Rahma G
Bioorg Chem; 2019 Sep; 90():103045. PubMed ID: 31212178
[TBL] [Abstract][Full Text] [Related]
27. Induction of apoptosis, cytotoxicity and radiosensitization by novel 3,4-dihydroquinazolinone derivatives.
Soliman AM; Khalil A; Ramadan E; Ghorab MM
Bioorg Med Chem Lett; 2021 Oct; 49():128308. PubMed ID: 34363937
[TBL] [Abstract][Full Text] [Related]
28. Design, Synthesis, Molecular Docking, and Biological Studies of New Heterocyclic Compounds Derived from β-Diketones as Novel EGFR and Pim-1 Inhibitors Endowed with AntitumorActivity.
Mohareb RM; Bagato NMA; Radwan IT
Anticancer Agents Med Chem; 2022; 22(14):2558-2576. PubMed ID: 35023461
[TBL] [Abstract][Full Text] [Related]
29. 3'-(4-(Benzyloxy)phenyl)-1'-phenyl-5-(heteroaryl/aryl)-3,4-dihydro-1'H,2H-[3,4'-bipyrazole]-2-carboxamides as EGFR kinase inhibitors: Synthesis, anticancer evaluation, and molecular docking studies.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Pottoo FH; Jha M
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900262. PubMed ID: 32003485
[TBL] [Abstract][Full Text] [Related]
30. Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability.
Ihmaid SK; Alraqa SY; Aouad MR; Aljuhani A; Elbadawy HM; Salama SA; Rezki N; Ahmed HEA
Bioorg Chem; 2021 Jun; 111():104835. PubMed ID: 33798850
[TBL] [Abstract][Full Text] [Related]
31. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, molecular docking, and anticancer evaluations of 1-benzylquinazoline-2,4(1H,3H)-dione bearing different moieties as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; El-Hddad SSA
Arch Pharm (Weinheim); 2020 Aug; 353(8):e2000068. PubMed ID: 32510731
[TBL] [Abstract][Full Text] [Related]
33. Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors.
Nawaz F; Alam O; Perwez A; Rizvi MA; Naim MJ; Siddiqui N; Firdaus JU; Rahman S; Jha M; Sheikh AA
Anticancer Agents Med Chem; 2021; 21(1):42-60. PubMed ID: 32718297
[TBL] [Abstract][Full Text] [Related]
34. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition,
Othman DIA; Hamdi A; Tawfik SS; Elgazar AA; Mostafa AS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166037. PubMed ID: 36651111
[TBL] [Abstract][Full Text] [Related]
35. Design, Synthesis, Molecular Docking, and Biological Evaluation of Isatin-Based Fused Heterocycles As Epidermal Growth Factor Receptor Inhibitors.
Kumar A; Kumar B; Bhatia R
Assay Drug Dev Technol; 2023 Jul; 21(5):222-233. PubMed ID: 37439798
[TBL] [Abstract][Full Text] [Related]
36. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
38. New 2-alkoxycyanopyridine derivatives as inhibitors of EGFR, HER2, and DHFR: Synthesis, anticancer evaluation, and molecular modeling studies.
Hawas SS; El-Sayed SM; Elzahhar PA; Moustafa MA
Bioorg Chem; 2023 Dec; 141():106874. PubMed ID: 37769524
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
[TBL] [Abstract][Full Text] [Related]
40. Introducing novel potent anticancer agents of 1H-benzo[f]chromene scaffolds, targeting c-Src kinase enzyme with MDA-MB-231 cell line anti-invasion effect.
Ahmed HEA; El-Nassag MAA; Hassan AH; Okasha RM; Ihmaid S; Fouda AM; Afifi TH; Aljuhani A; El-Agrody AM
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1074-1088. PubMed ID: 29923425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
